匯量科技(01860.HK):總裁兼執行董事曹曉歡獲委任為首席執行官
格隆匯 1 月 14日丨匯量科技(01860.HK)宣佈,由於公司決策機制、管治架構及運營制度的全面與成熟發展,以及段威決定致力於公司創新業務戰略規劃及生態業務佈局,段威已辭任公司首席執行官職務,自2021年1月14日起生效。段威將繼續擔任公司董事會主席、執行董事及提名委員會主席。
同日宣佈,公司總裁兼執行董事曹曉歡已獲委任為公司首席執行官以替任段威,自2021年1月14日起生效。經段威與曹曉歡多年的密切合作,彼等對公司主要業務佈局及發展方向已達成共識。董事會相信,曹曉歡於擔任公司總裁期間所公認在公司業務策略制定以及穩定運營方面的出色領導及決策能力將對公司有利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.